Loading…
Delcath Systems, Inc. is projected to rise to $18.09 by 2027, a +39% move from its current price of $13.01. DCTH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $12.70 | $13.01 | $13.33 | +0.03% |
| Jul 13 | $12.58 | $13.02 | $13.47 | +0.06% |
| Jul 14 | $12.49 | $13.02 | $13.58 | +0.09% |
| Jul 15 | $12.41 | $13.03 | $13.67 | +0.12% |
| Jul 16 | $12.35 | $13.03 | $13.75 | +0.15% |
| Jul 17 | $12.29 | $13.03 | $13.83 | +0.18% |
| Jul 18 | $12.23 | $13.04 | $13.90 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.23 | $13.04 | $13.90 | +0.21% |
| Week 2 | $11.94 | $13.06 | $14.30 | +0.41% |
| Week 3 | $11.72 | $13.09 | $14.62 | +0.62% |
| Week 4 | $11.55 | $13.12 | $14.90 | +0.83% |
| Week 5 | $11.40 | $13.14 | $15.16 | +1.03% |
| Week 6 | $11.27 | $13.17 | $15.40 | +1.24% |
| Week 7 | $11.15 | $13.20 | $15.63 | +1.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Delcath Systems, Inc. is a healthcare company focused on interventional oncology, with a primary focus on the treatment of primary and metastatic liver cancers in the United States and Europe.
Its lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Delcath Systems, Inc. (DCTH) is a healthcare company focused on interventional oncology.
The stock is currently priced at $12.94, with a market cap of $446.71M and a rank of 3130. These figures place it among smaller-cap healthcare stocks with specialized liver cancer therapies.
The verified forecast shows a clear upside path beyond the current price, with 2026 averaging $12.94 (neutral, ROI 0%), and higher averages in subsequent years—$17.28 in 2027, $21.64 in 2028, $27.00 in 2029, and $31.04 in 2030—progressing to $214.61 on average by 2050 with a max of $383.62. The outlook shifts from neutral in 2026 to bullish in later years.
A major floor 33.9% below — a decisive break under it would weaken the trend.
The nearest floor, 20.6% below — buyers have tended to step in here.
The nearest ceiling, 3.9% above — a clean break opens room to run.
A major ceiling 19.0% above — clearing it would confirm fresh momentum.
Key DCTH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DCTH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.31 | Sell | $13.19 | Sell |
| MA 10 | $13.11 | Sell | $13.01 | Buy |
| MA 20 | $12.50 | Buy | $12.57 | Buy |
| MA 50 | $11.60 | Buy | $11.77 | Buy |
| MA 100 | $10.67 | Buy | $11.15 | Buy |
| MA 200 | $10.35 | Buy | $10.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.76 | Neutral |
| Stoch RSI (14) | 29.28 | Neutral |
| CCI (20) | 55.43 | Neutral |
| Williams %R (14) | -25.37 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 5.86 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 74.63 | Neutral |
| TRIX (15) | 0.64 | Buy |
| Awesome (5,34) | 1.47 | Buy |
| Ultimate (7,14,28) | 61.76 | Neutral |
| Momentum (10) | 0.69 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 13.36 | Sell |
| ADX (14) | 23.84 | Buy |
| ATR (14) | 0.30 | Info |
The 30-day technical picture is bullish, with RSI(14) at 60 and prices trading above key moving averages. The SMA50 is $11.15 and the SMA200 is $10.26, suggesting a constructive near-term trend.
Support is identified at $10.33 and resistance at $12.32, while the 30-day trading range spans from $10.98 to $15.24. Annualized volatility stands at 50%, signaling notable price movement potential over the next month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.60 | $13.01 | $17.07 | 0% | Neutral | |
| $14.56 | $18.09 | $23.69 | +39% | Bullish | |
| $17.81 | $22.68 | $30.70 | +74% | Bullish | |
| $22.31 | $28.98 | $40.26 | +123% | Bullish | |
| $25.68 | $33.95 | $48.21 | +161% | Bullish | |
| $27.50 | $36.96 | $53.49 | +184% | Bullish | |
| $31.97 | $43.61 | $64.22 | +235% | Bullish | |
| $33.47 | $46.29 | $69.25 | +256% | Bullish | |
| $37.59 | $52.68 | $79.95 | +305% | Bullish | |
| $50.00 | $70.97 | $109.16 | +445% | Bullish | |
| $69.55 | $104.52 | $170.12 | +703% | Bullish | |
| $160.68 | $266.01 | $470.30 | +19.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.60 | $13.01 | $15.37 | +0.00% |
| August 2026 | $11.22 | $13.20 | $15.92 | +1.47% |
| September 2026 | $11.29 | $13.36 | $16.28 | +1.23% |
| October 2026 | $10.97 | $13.06 | $16.04 | -2.25% |
| November 2026 | $10.97 | $13.12 | $16.23 | +0.43% |
| December 2026 | $11.42 | $13.71 | $17.07 | +4.51% |
Click any year to see its month-by-month DCTH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The DCTH price prediction for 2026 points to an average of $13.01 (low $8.60, high $17.07) — a potential gain of 0% on today's $13.01. Price action looks broadly range-bound.
In 2027, DCTH is projected to trade between $14.56 and $23.69, averaging $18.09 — a potential gain of +39% from today's $13.01. That is up +39% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Delcath Systems, Inc.'s 2028 outlook centres on $22.68, within a $17.81 to $30.70 range. That is up +25% on the projected 2027 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2029, DCTH could reach as high as $40.26, with a base case around $28.98 and support toward $22.31 — roughly +123% from $13.01. Buyers look set to stay in control over this stretch.
Expect DCTH to range from $25.68 to $48.21 through 2030. The $33.95 average target implies a +161% move from current prices. That is up +17% on the projected 2029 average. Momentum favours further upside here.
The DCTH price prediction for 2031 points to an average of $36.96 (low $27.50, high $53.49) — a potential gain of +184% on today's $13.01. Buyers look set to stay in control over this stretch.
In 2032, DCTH is projected to trade between $31.97 and $64.22, averaging $43.61 — a potential gain of +235% from today's $13.01. That is up +18% on the projected 2031 average. Momentum favours further upside here.
Delcath Systems, Inc.'s 2033 outlook centres on $46.29, within a $33.47 to $69.25 range. That is up +6% on the projected 2032 average. That marks a +256% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, DCTH could reach as high as $79.95, with a base case around $52.68 and support toward $37.59 — roughly +305% from $13.01. Momentum favours further upside here.
Expect DCTH to range from $50.00 to $109.16 through 2035. The $70.97 average target implies a +445% move from current prices. That is up +35% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The DCTH price prediction for 2040 points to an average of $104.52 (low $69.55, high $170.12) — a potential gain of +703% on today's $13.01. Momentum favours further upside here.
In 2050, DCTH is projected to trade between $160.68 and $470.30, averaging $266.01 — a potential gain of +19.4x from today's $13.01. That is up +155% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DCTH today (≈ 76.863951 DCTH) could be worth
$20,446.9
+$19,446.9 (+1945%) by 2050 · US Dollar
Based on the average projected DCTH price of $266.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DCTHwould be worth at today's price.
$1,000 invested in DCTH on Jul 10, 2025 (≈ 79.681274 DCTH) would be worth
$1,036.65
+$36.65 (+3.7%) today · 1.04× · US Dollar
Based on a DCTH entry price of $12.55 vs. today's $13.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.2 | $985.61 | -1.4% |
| 1 month ago | $11.19 | $1,162.65 | +16.3% |
| 3 months ago | $10.04 | $1,295.82 | +29.6% |
| 6 months ago | $10.29 | $1,264.33 | +26.4% |
| 1 year ago | $12.55 | $1,036.65 | +3.7% |
| All time (5.0y) ago | $11.09 | $1,173.13 | +17.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DCTH forecast.
Our base-case forecast reaches $26.00 around 2029.
Implied market cap at $26.00: $897.56M
Across the multi-year forecast, the average price climbs from $12.94 in 2026 to $31.04 in 2030 and to $214.61 in 2050, with higher potential in between. The max forecast moves from $17.03 in 2026 to $44.37 in 2030, and up to $383.62 in 2050, signaling substantial upside potential.
ROI figures rise from 0% in 2026 to 33.5% in 2027, 67.2% in 2028, 108.7% in 2029, 139.9% in 2030, 161.3% in 2031, 199.3% in 2032, 210.7% in 2033, 257.4% in 2034, and 374.4% in 2035, then 573.3% in 2040 and 1558.5% in 2050.
Sentiment is Neutral in 2026 and bullish from 2027 onward, reflecting a broad expectation of upside while acknowledging the inherent uncertainty of long-range forecasts. These figures are estimates, not guarantees, and depend on factors including market conditions and clinical outcomes.
Tap a question to reveal the answer.
2030 avg $31.04, ROI 139.9%.
Forecasts show rising averages and bullish sentiment from 2027 onward, with 2030 avg $31.04, 2040 avg $87.13, 2050 avg $214.61, and ROI reaching 139.9%, 573.3%, and 1558.5% respectively.
Yes. The 2035 forecast shows min $42.91, avg $61.39, max $95.22, indicating upside beyond $50 by 2035 on average.
Current price $12.94; market cap $446.71M.
2040 avg $87.13; min $57.40; max $143.14; ROI 573.3%; sentiment bullish.
Delcath Systems, Inc. Community Discussion
0Share your Delcath Systems, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.